Find something to look at
Browse by category, see the connections as a graph, check out what's being tested in patients right now, or see the latest FDA approvals.
Disease ↔ gene ↔ drug
See the connections as a graph
Three things connect everything: diseases, the genes involved in them, and the drugs that act on those genes. Pick a disease and we'll draw the picture: which genes drive it, and which existing drugs hit those genes.
By category
Pick a body system or disease family. Click any condition to see drugs that might also help it.
Cancer
Solid tumors, blood cancers, and rare oncology.
Heart & vessels
Cardiovascular disease, blood pressure, clotting.
Brain & nerves
Neurodegeneration, dementia, movement, headache.
Mental health
Mood, anxiety, attention, addiction.
Immune & autoimmune
When the body's defenses go wrong.
Metabolism & weight
Diabetes, obesity, thyroid, liver, hormones.
Drugs being tested in patients right now
The most-recent Phase II / Phase III studies that are actively recruiting people. Pulled live from ClinicalTrials.gov.
- A Study of BGM0504 in Early T2DM With ObesityPHASE3For: Type 2 Diabetes (T2DM)BGM0504semaglutideNCT07743983● recruiting
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3For: Diabetic Macular Edema, DME +1 moreEYP-1901Aflibercept (2.0 mg)NCT07449923● recruiting
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent…PHASE3For: Hidradenitis SuppurativaUpadacitinibPlaceboNCT05889182● recruiting
- Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway…PHASE3For: Obesity, Obstructive Sleep ApneaMaridebart cafraglutidePlaceboNCT07225686● recruiting
- Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSPHASE3For: Amyotrophic Lateral SclerosisPridopidinePlaceboNCT07322003● recruiting
- A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen)…PHASE3For: Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) +12 moreAOC 1044PlaceboNCT07587242● recruiting
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial S…PHASE3For: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma +6 moreCarboplatinHyaluronidase-zzxf/Pert…PaclitaxelTrastuzumab/Hyaluronida…NCT05256225● recruiting
- Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney…PHASE2, PHASE3For: Proteinuric Kidney DiseaseVX-147PlaceboNCT05312879● recruiting
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-859…PHASE2, PHASE3For: Human Immunodeficiency Virus Type 1 (HIV-1) InfectionISLULOBIC/FTC/TAFPlacebo for BIC/FTC/TAFNCT07266831● recruiting
- AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weig…PHASE3For: Diabetes Mellitus, Overweight +1 moreNNC0487-0111Placebo (matched to NNC…NCT07533175● recruiting
- (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic M…PHASE2, PHASE3For: Indolent Systemic Mastocytosis, Smoldering Systemic MastocytosisElenestinibPlaceboNCT04910685● recruiting
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaPHASE3For: Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological FeaturesMosunetuzumabRituximabRituximab and Hyaluroni…NCT06337318● recruiting
Notable recent FDA approvals
A hand-picked tour of new medicines that reached patients in the last couple of years. Click into any one to see what else it might also help.
Leqembi
2023lecanemabApproved for early Alzheimer's disease.First antibody to slow Alzheimer's progression, by clearing amyloid plaques from the brain.
See its profile →Kisunla
2024donanemabApproved for early Alzheimer's disease.Second-generation amyloid antibody — limited-duration treatment, stops once plaques clear.
See its profile →Rezdiffra
2024resmetiromApproved for advanced fatty liver disease (MASH).First drug ever approved for non-alcoholic steatohepatitis — a condition affecting tens of millions.
See its profile →Zepbound
2023tirzepatideApproved for obesity.GLP-1/GIP dual receptor agonist; the most effective weight-loss medication in trials to date.
See its profile →Winrevair
2024sotaterceptApproved for pulmonary arterial hypertension.First-in-class activin signaling inhibitor for a rare, progressive lung condition.
See its profile →Amtagvi
2024lifileucelApproved for advanced melanoma.First cellular therapy for a solid tumor — uses the patient's own T cells against the cancer.
See its profile →Truqap
2023capivasertibApproved for HR+/HER2- breast cancer.Targets the AKT pathway in tumors that have become resistant to hormone therapy.
See its profile →Wegovy
2024semaglutideApproved for cardiovascular risk reduction.Already approved for obesity; new indication shows it cuts heart-attack risk in overweight adults.
See its profile →